AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
dasiglucagon 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| glucagon-like peptide (GLP) analogues and agonists | 5447 | 1544300-84-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Dasiglucagon is a glucagon receptor agonist, which increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for dasiglucagon to produce an antihypoglycemic effect.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 22, 2021 | FDA | ZEALAND PHARMA AS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | H04AA02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PANCREATIC HORMONES GLYCOGENOLYTIC HORMONES Glycogenolytic hormones |
| FDA PE | N0000009345 | Increased Glycogenolysis |
| FDA EPC | N0000190852 | Antihypoglycemic Agent |
| FDA MoA | N0000193923 | Glucagon Receptor Agonists |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:76916 | hyperglycemic agent |
Related Drugs by ATC class:
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypoglycemia due to diabetes mellitus | indication | 237633009 | |
| Insulinoma | contraindication | 302822000 | DOID:3892 |
| Pheochromocytoma | contraindication | 302835009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML) | ZEGALOGUE | ZEALAND PHARMA | N214231 | March 22, 2021 | DISCN | SOLUTION | SUBCUTANEOUS | 11795204 | Jan. 6, 2034 | METHOD OF TREATING DIABETIC HYPOGLYCEMIA |
| EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML) | ZEGALOGUE (AUTOINJECTOR) | ZEALAND PHARMA | N214231 | March 22, 2021 | DISCN | SOLUTION | SUBCUTANEOUS | 11795204 | Jan. 6, 2034 | METHOD OF TREATING DIABETIC HYPOGLYCEMIA |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML) | ZEGALOGUE | ZEALAND PHARMA | N214231 | March 22, 2021 | DISCN | SOLUTION | SUBCUTANEOUS | March 22, 2026 | NEW CHEMICAL ENTITY |
| EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML) | ZEGALOGUE (AUTOINJECTOR) | ZEALAND PHARMA | N214231 | March 22, 2021 | DISCN | SOLUTION | SUBCUTANEOUS | March 22, 2026 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glucagon receptor | GPCR | AGONIST | EC50 | 11 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| D11359 | KEGG_DRUG |
| AD4J2O47FQ | UNII |
| C5139868 | UMLSCUI |
| CHEBI:757192 | CHEBI |
| CHEMBL4297741 | ChEMBL_ID |
| 126961379 | PUBCHEM_CID |
| DB15226 | DRUGBANK_ID |
| CHEMBL4650274 | ChEMBL_ID |
| 10480 | INN_ID |
| C000710373 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4040381 | VANDF |
| 39407 | MMSL |
| d09724 | MMSL |
| 018680 | NDDF |
| 018681 | NDDF |
| 2535233 | RXNORM |
| AD4J2O47FQ | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Zegalogue | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-1912 | INJECTION, SOLUTION | 0.60 mg | SUBCUTANEOUS | NDA | 29 sections |
| Zegalogue | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-1913 | INJECTION, SOLUTION | 0.60 mg | SUBCUTANEOUS | NDA | 29 sections |